EVOLUTION AT MERCK - INVENTING FOR LIFE
KEYTRUDA: ROBUST I-O PROGRAM IN ADJUVANT /
NEOADJUVANT AND EARLIER LINES OF THERAPY
MERCK
INVENTING FOR LIFE
2018
Adjuvant Melanoma (KN-054)
APPROVED
2021
NSCLC Adjuvant (KN-091)
HNSCC Adjuvant /
Neoadjuvant (KN-689)
2023
Gastric & Esophageal Adjuvant
/ Neoadjuvant (KN-585)
HNSCC Locally Advanced
(KN-412)
2025
Adjuvant / Neoadjuvant MIBC (KN-866)
Adjuvant / Neoadjuvant MIBC (KN-905)
HCC Adjuvant (KN-937)
NSCLC Stage I/lla (KN-867)
#
Dr. Roy Baynes H
2019
TNBC Neoadjuvant /
Adjuvant (KN-522)
CSCC Locally Advanced
(KN-629)
2022
Adjuvant Melanoma (KN-716)
RCC Adjuvant (KN-564)
2L NMIBC (KN-057)
MIBC Locally Advanced
(KN-676)
2024
NSCLC Neoadjuvant (KN-671)
2026+
TNBC Adjuvant (KN-242)
CSCC Locally Advanced (KN-630)
ER+ / HER2- Breast Cancer
Adjuvant / Neoadjuvant (KN-756)
Many registrational trials with readouts over the coming years
52
62View entire presentation